Pd-l1

Edit

Telangana Inc seeks more capital spending ahead of budget 2026-27

The Times of India 20 Mar 2026

HYDERABAD ... For 2026-27, he said industry expects a 5% to 7% increase in overall expenditure despite resource constraints.Kumar said nearly 75% of the budget is currently absorbed by revenue expenditure, leaving limited room for capital creation.

Edit

Village council takes aim at dam rehabilitation projects after report

The Citizen 14 Mar 2026

The Goodrich Dam looking south. Photo. Patrick McAbee. Goodrich — On Monday night the village council moved one step closer to a proposal to rehabilitate the century-old Goodrich dam following a presentation from Flint-based Wade Trim ... Goodrich Dam ... ....

Edit

ORYZON expands patent protection for iadademstat with grant decision in Mexico covering combinations with PD-1/PD-L1 inhibitors (ASEBIO - Asociación Española de Bioempresas)

Public Technologies 13 Mar 2026

) Partners Key combination for the treatment of Small Cell Lung Cancer . [...] ... Attachments Original document Permalink.

Edit

ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors

Nasdaq Globe Newswire 12 Mar 2026

(ISIN Code ... .

Edit

ORYZON expands patent protection for iadademstat with grant decision in Mexico covering combinations with PD-1/PD-L1 inhibitors (Oryzon Genomics SA)

Public Technologies 12 Mar 2026

... covering combinations with PD-1/PD-L1 inhibitors ... Iadademstat is currently being investigated in combination with PD-L1 inhibitors in extensive-stage SCLC (ES-SCLC) in two ongoing clinical trials.

Edit

Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer

PR Newswire 09 Mar 2026

Opamtistomig is a uniquely engineered bispecific antibody designed to simultaneously block PD-1/L1-mediated immune suppression and selectively activate the 4-1BB co-stimulatory pathway.

Edit

PD-L1 Biomarker Testing Market Research Report 2026 - Global Industry Size, Share, Trends, Opportunity, and ...

Nasdaq Globe Newswire 26 Feb 2026

The PD-L1 Biomarker Testing Market offers opportunities driven by the rising incidence of non-small cell lung cancer and the expanding use ...

Edit

Jupiter DAO Backs Net Zero Emissions Plan With 75% Vote, Postpones Jupuary And Halts New Supply

NULLTX 22 Feb 2026

JupiterExchange community members have concluded a closely watched governance vote, with a decisive 75% majority backing the “Net Zero Emissions” proposal ... New ... pic.twitter.com/zcrQjS3jga. — SolanaFloor (@SolanaFloor) February 22, 2026 ... Disclosure.

Edit

US military assets in the Middle East

The New Arab 21 Feb 2026

The USS Gerald R. Ford aircraft carrier entered the Mediterranean Sea on Friday, further boosting American firepower in a region that has seen a massive military buildup ahead of potential strikes against Iran ... Ships ... Aircraft ... Air defenses ... ....

Edit

Despite illness, Tyler Tanner galvanizes Vanderbilt basketball almost to win

Columbia Daily Herald 19 Feb 2026

Tyler Tanner was sick when Vanderbilt basketball hit the road to face Missouri and, his coach said, you could tell in the first half. Not by the second half, though ... 18. They had gone down by 21 late in the second half when Tanner took over ... ... 21.

Edit

PD-1 and PD-L1 Inhibitors Competitive Landscape Report 2026: Comprehensive Insights on 200+ Drugs from Over ...

Nasdaq Globe Newswire 18 Feb 2026

The PD-1 and PD-L1 inhibitors market offers significant opportunities by expanding cancer treatment options using immunotherapy.

Edit

US to send more weapons to Philippines

NWA Online 18 Feb 2026

.

Edit

PD-1/PD-L1 Checkpoint Inhibitors Market Research and Global Forecast Report 2026-2032

Nasdaq Globe Newswire 17 Feb 2026

The PD-1/PD-L1 market offers opportunities in therapy combinations, real-world data use, and digital patient support ...

Edit

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or ...

Hastings Tribune 12 Feb 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb 11, 2026-- ... .

Edit

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC) (Agilent Technologies Inc)

Public Technologies 11 Feb 2026

PD-L1 IHC 22C3 pharmDx, Code SK006, enables pathologists to assess PD-L1 expression at the time of diagnosis, supporting informed treatment decisions in a disease where therapeutic options remain limited for many patients.

Podcasts:

Latest News for: pd-l1

Telangana Inc seeks more capital spending ahead of budget 2026-27

Village council takes aim at dam rehabilitation projects after report

ORYZON expands patent protection for iadademstat with grant decision in Mexico covering combinations with PD-1/PD-L1 inhibitors (ASEBIO - Asociación Española de Bioempresas)

ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors

ORYZON expands patent protection for iadademstat with grant decision in Mexico covering combinations with PD-1/PD-L1 inhibitors (Oryzon Genomics SA)

Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer

PD-L1 Biomarker Testing Market Research Report 2026 - Global Industry Size, Share, Trends, Opportunity, and ...

Jupiter DAO Backs Net Zero Emissions Plan With 75% Vote, Postpones Jupuary And Halts New Supply

US military assets in the Middle East

Despite illness, Tyler Tanner galvanizes Vanderbilt basketball almost to win

PD-1 and PD-L1 Inhibitors Competitive Landscape Report 2026: Comprehensive Insights on 200+ Drugs from Over ...

US to send more weapons to Philippines

PD-1/PD-L1 Checkpoint Inhibitors Market Research and Global Forecast Report 2026-2032

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or ...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC) (Agilent Technologies Inc)

Article Search

EXPLORE WN.com